Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study
This pilot clinical trial will evaluate the initial safety and feasibility of intestinal microbiota transplantation (IMT) in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04884971
- Testing
- Intestinal microbiota transplant (IMT)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Minnesota
Idiopathic Pulmonary Arterial Hypertension
Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb® Ig flex adsorber treatment (as an add-on to conventional treatment) used exclusively with the LIFE 18® apheresis system for…
- Trial name
- NCT01613287
- Testing
- TheraSorb® - Ig flex
- Where
- 4 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Miltenyi Biotec B.V. & Co. KG
Pulmonary Arterial Hypertension
Anastrozole in Patients With Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to study the safety and efficacy of anastrozole in adults diagnosed with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated.
- Trial name
- AIPH (NCT01545336)
- Testing
- Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT05764265
- Testing
- LTP001
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension
The 6th World Symposium on Pulmonary Hypertension, pre-capillary pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) >20 mm Hg with a pulmonary arterial wedge pressure (PAWP) ≤15 mm Hg and…
- Trial name
- NCT07214129
- Testing
- Nebulized nitroglycerin
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Mansoura University
Pulmonary Arterial Hypertension
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.
- Trial name
- TripleTRE-NIS (NCT06445673)
- Where
- 18 sites in Austria, Czechia and 7 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Anxiety Self-management Intervention for Pulmonary Hypertension
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Anxiety, Anxiety Disorders
- Trial name
- NCT04450862
- Testing
- Cognitive Behavioural therapy self help intervention for anxiety
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- University of Sheffield
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease…
- Trial name
- PPHNet (NCT02249923)
- Where
- 14 sites in United States, Canada
- Volunteers
- 2,500 people
- Sponsor
- New York Medical College
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
- Trial name
- PHiano (NCT01265888)
- Testing
- Inhaled Nitric Oxide
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Geno LLC
Pulmonary Arterial Hypertension, HIV Infection
Auto-immunity and Pulmonary Arterial Hypertension
The investigators have recently evidenced the presence of antibodies to endothelial cells and fibroblasts in patients with idiopathic or SSc-associated PAH.
- Conditions
- Pulmonary Arterial Hypertension, HIV Infection, Congenital Heart Defect, Systemic Sclerosis
- Trial name
- Auto-HTAP (NCT01208792)
- Testing
- skin biopsy, Blood Sample
- Where
- 3 sites in France
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Prospective, multi-center, open-label, single-arm, Phase 3b extension study of macitentan in patients with PAH. To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment…
- Trial name
- NCT02112487
- Testing
- Macitentan
- Where
- 32 sites in France, Italy and 1 more
- Volunteers
- 88 people
- Sponsor
- Actelion
Idiopathic Pulmonary Arterial Hypertension
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs.
- Trial name
- NCT00372346
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Pulmonary Arterial Hypertension, Renal Dysfunction
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
This is a single-center, open-label, single-dose evaluation of 1 mg UT-15C SR pharmacokinetics, safety, and tolerability in subjects with normal, mild, moderate and end stage renal disease (ESRD; on dialysis).
- Trial name
- NCT01131845
- Testing
- UT-15C SR (treprostinil diethanolamine)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Asthma, Atrial Fibrillation
The Living With a Long-Term Condition Study
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs).
- Conditions
- Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders
- Trial name
- LTC (NCT06072287)
- Testing
- Living with LTC Questionnaire
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension
The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that…
- Trial name
- FUTURE-1 (NCT00319267)
- Testing
- Bosentan
- Volunteers
- 36 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
The purpose of this multicentre, open label, single-arm study in approximately 20 adult patients is to evaluate the Impact on lifestyle of a new thermo stable formulation of epoprostenol sodium in subjects with Pulmonary Arterial…
- Trial name
- NCT01462565
- Testing
- current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Pulmonary Hypertension and Anastrozole Trial
The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in…
- Trial name
- PHANTOM (NCT03229499)
- Testing
- Anastrozole
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on…
- Trial name
- HYPERION (NCT04811092)
- Testing
- Sotatercept
- Where
- 152 sites in United States, Argentina and 25 more
- Volunteers
- 321 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) can result in right ventricular failure and death. Anakinra has been used in patients with left sided heart failure, and the present study looks to determine if anakinra is safe and effective…
- Trial name
- NCT03057028
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Virginia Commonwealth University
Pulmonary Arterial Hypertension (PAH)
SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
The study aims to see how 24 weeks of triple therapy-an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept-affects pulmonary vascular resistance (PVR) in patients with newly diagnosed…
- Trial name
- SIRIUS (NCT07266519)
- Testing
- Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg, Sotatercept
- Volunteers
- 25 people
- Sponsor
- Philipps University Marburg